Impact of metabolic syndrome on progression of aortic stenosis: Influence of age and statin therapy

Journal of the American College of Cardiology

Volumn 60, Issue 3, 2012, Pages 216-223

  Capoulade, Romain ^a   Clavel, Marie Annick ^a   Dumesnil, Jean G ^a   Chan, Kwan L ^b   Teo, Koon K ^c   Tam, James W ^d   Côté, Nancy ^a   Mathieu, Patrick ^a   Després, Jean Pierre ^a   Pibarot, Philippe ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d ST BONIFACE GENERAL HOSPITAL   (Canada)

Author keywords

aortic stenosis; Doppler echocardiography; metabolic syndrome; obesity; statins

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN;

ADULT; AGE DISTRIBUTION; AGED; AORTA STENOSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG USE; EVENT FREE SURVIVAL; FEMALE; HEART DEATH; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AORTIC VALVE STENOSIS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863646913     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.03.052     Document Type: Article

References (30)

1. R.V. Freeman, C.M. Otto Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies Circulation 111 2005 3316 3326
2. M.F. Bellamy, P.A. Pellikka, K.W. Klarich, A.J. Tajik, M. Enriquez-Sarano Association of cholesterol levels, hydroxymethylglutaryl coenzyme-a reductase inhibitor treatment, and progression of aortic stenosis in the community J Am Coll Cardiol 40 2002 1723 1730
3. G.M. Novaro, I.Y. Tiong, G.L. Pearce, M.S. Lauer, D.L. Sprecher, B.P. Griffin Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis Circulation 104 2001 2205 2209
4. R. Rosenhek, F. Rader, N. Loho Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis Circulation 110 2004 1291 1295
5. L.M. Moura, S.F. Ramos, J.L. Zamorano Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis J Am Coll Cardiol 49 2007 554 561
6. S.J. Cowell, D.E. Newby, R.J. Prescott A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis N Engl J Med 352 2005 2389 2397
7. A.B. Rossebo, T.R. Pedersen, K. Boman Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis N Engl J Med 359 2008 1343 1356
8. K.L. Chan, K. Teo, J.G. Dumesnil, A. Ni, J. Tam Effect of lipid lowering with rosuvastatin on progression of aortic stenosis Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial Circulation 121 2010 306 314
9. M. Briand, I. Lemieux, J.G. Dumesnil Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis J Am Coll Cardiol 47 2006 2229 2236
10. R. Katz, N.D. Wong, R. Kronmal Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis Circulation 113 2006 2113 2119
11. M. Briand, P. Pibarot, J.P. Despres Metabolic syndrome is associated with faster degeneration of bioprosthetic valves Circulation 114 2006 1512 1517
12. K.L. Chan, K. Teo, J. Tam, J.G. Dumesnil Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial Am Heart J 153 2007 925 931
13. T.G. Lohman, A.F. Roche, R. Martorell The Airlie (VA) Consensus Conference T.G. Lohman, A.F. Roche, R. Martorell, Anthropometric Standardization Reference Manual 1988 Human Kinetics Champaign, IL 39 80
14. A.C. St Pierre, B. Cantin, G.R. Dagenais Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study Arterioscler Thromb Vasc Biol 25 2005 553 559
15. D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
16. National Cholesterol Education Program Expert Panel Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adults Treatment Panel III) JAMA 285 2001 2486 2492
17. R. Rosenhek, T. Binder, G. Porenta Predictors of outcome in severe, asymptomatic aortic stenosis N Engl J Med 343 2000 611 617
18. R.M. Lang, M. Bierig, R.B. Devereux Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology J Am Soc Echocardiogr 18 2005 1440 1463
19. A. Pagé, J.G. Dumesnil, M.A. Clavel Metabolic syndrome is associated with more pronounced impairment of LV geometry and function in patients with calcific aortic stenosis: a substudy of the ASTRONOMER trial (Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin) J Am Coll Cardiol 55 2010 1867 1874
20. Z. Hachicha, J.G. Dumesnil, P. Pibarot Usefulness of the valvuloarterial impedance to predict adverse outcome in asymptomatic aortic stenosis J Am Coll Cardiol 54 2009 1003 1011
21. D. Mohty, P. Pibarot, J.P. Despres Age-related differences in the pathogenesis of calcific aortic stenosis: the potential role of resistin Int J Cardiol 142 2010 126 132
22. K. Akat, J.J. Kaden, F. Schmitz Calcium metabolism in adults with severe aortic valve stenosis and preserved renal function Am J Cardiol 105 2010 862 864
23. M.K. Osako, H. Nakagami, N. Koibuchi Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification Circ Res 107 2010 466 475
24. K.K. Koh, M.J. Quon, S.H. Han, Y. Lee, S.J. Kim, E.K. Shin Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients J Am Coll Cardiol 55 2010 1209 1216
25. P.S. Sever, B. Dahlof, N.R. Poulter Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 2003 1149 1158
26. R. Collins, J. Armitage, S. Parish, P. Sleigh, R. Peto MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 2003 2005 2016
27. P.M. Ridker, E. Danielson, F.A. Fonseca Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
28. D.D. Waters, J.E. Ho, D.A. DeMicco Predictors of new-onset diabetes in patients treated with atorvastatin J Am Coll Cardiol 14 2011 1535 1545
29. J.P. Despres, I. Lemieux Abdominal obesity and metabolic syndrome Nature 444 2006 881 887
30. C. Baigent, A. Keech, P.M. Kearney Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278